Potential of typhoid conjugate vaccines in Pakistan

Typhoid, a serious enteric fever spread through contaminated food and water, is a substantial public health issue that disproportionately impacts children and marginalized populations in Asia and sub-Saharan Africa. The Global Burden of Disease (GBD) study estimates that, in 2016, there were nearly 12 million typhoid cases and more than 128,000 typhoid deaths worldwide. Additionally, strains of drug-resistant typhoid are spreading, causing global concern.

TYPHOID CONJUGATE VACCINES

Typhoid vaccination can reduce the need for antibiotics, slow expansion of drug-resistant strains, and save lives. Newly licensed typhoid conjugate vaccines (TCVs) have several advantages over earlier typhoid vaccines. They:

- provide longer-lasting protection up to 5 years;
- require only one dose; and
- are suitable for young children over 6 months.

These qualities will allow better protection for younger children and expanded coverage through inclusion in routine childhood immunization programs.

WHO SAGE REVIEW

In October 2017, the World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization recommended that typhoid-endemic countries introduce TCVs in a single dose for infants and children over 6 months of age, accompanied by catch-up vaccination campaigns for children up to 15 years of age, where feasible. Additionally, SAGE recommended prioritizing TCV introduction in countries with a high burden of disease and/or evidence of antimicrobial resistance (AMR). TCVs were also recommended in response to typhoid outbreaks and in groups at high risk or with high transmission potential.

AN OPPORTUNITY FOR PAKISTAN

TCVs could have a substantial benefit in Pakistan, where typhoid inflicts a significant public health burden. The GBD estimates that, in 2016, Pakistan had:

- 574,424 typhoid cases, of which 61 percent were under 15 years of age;
- 7,811 typhoid deaths, of which 68 percent were under 15 years of age.

Pakistan is currently battling an outbreak of multidrug-resistant typhoid, which has infected more than 400 people and could spread widely. Typhoid also brings an economic burden. One study found that the average cost for a typhoid case in Pakistan was US$55. Analyses from other Asian countries have found that TCVs can be a cost-effective intervention.

References

3. October 2017 SAGE meeting summary.